Telix Pharmaceuticals (TLX) Goodwill (2024 - 2025)

Telix Pharmaceuticals (TLX) posted quarterly Goodwill of $199.0 million for Q4 2025, up 198.84% year-over-year from $66.6 million in Q4 2024, and up 198.84% quarter-over-quarter from $66.6 million in Q4 2024.

Telix Pharmaceuticals (TLX) Goodwill (2024 - 2025) Analysis & Trends

Telix Pharmaceuticals (TLX) has reported Goodwill for 2 consecutive years, with $199.0 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Goodwill rose 198.84% year-over-year to $199.0 million; the TTM figure through Dec 2025 stood at $199.0 million (up 198.84% YoY), while the FY2025 annual figure was $199.0 million, up 198.84% from the prior year.
  • Goodwill advanced to $199.0 million in Q4 2025 per TLX's latest filing, from $66.6 million in the prior quarter.
  • Across five years, Goodwill topped out at $199.0 million in Q4 2025 and bottomed at $66.6 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Telix Pharmaceuticals 4.00 Bn 3.86 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2025 198.99 Mn
Dec 31, 2024 66.59 Mn